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tive pulmonary diseases, asthma, coronary artery disease, diabetes, obesity, liver, 
or thyroid condition, cancer and stroke). Ordinary least square regression (OLS) 
and multinomial logistic regressions on low (< 1.0 mg/l), average (1-3 mg/l) and 
high (> 3 mg/l) were used to analyze the association between antidepressant use 
and CRP. Results: Antidepressant use was reported by 13% of the adults and the 
average CRP value for the sample was 4.85 mg/l (SE = 0.0113). 22% had low CRP, 
33% had average CRP and 45% had high CRP values. Average CRP values were not 
statistically different between antidepressant users and non-users. Other factors 
that were significantly associated with CRP were: perceived health status, smok-
ing and income. For example, adults with excellent perceived health status had 
significantly lower CRP values (p < 0.004) as compared to those with poor health 
status. ConClusions: In this population-based study, no statistically significant 
association between antidepressant use and inflammatory bio-markers were found 
in individuals with an inflammatory condition. Future research may need to focus 
on specific inflammatory conditions including depression.
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objeCtives: To estimate the annual aggregate expenditures of prescription phar-
maceuticals in the treatment of peripheral neuropathic pain in the United States 
over a seven year period. Methods: We utilized annually compiled data for the 
years 2005-2011 of the Medical Expenditure Panel Survey (MEPS), a publically avail-
able dataset to construct cross-sectional, representative estimates of medical 
expenses and utilization for the civilian, non-institutionalized US population. We 
identified cases using International Classification of Disease-Ninth Revision, Clinical 
Modification (ICD-9-CM) codes which denoted conditions prone to peripheral neu-
ropathy (diabetes mellitus and herpes zoster), or indicated peripheral neuropathy 
directly. These were associated with pharmacy records using Cerner Multum™ clas-
sifications for classes of medication commonly used for treating neuropathic pain. 
Prescriptions counts and costs were aggregated by year. Survey weighting, clustering 
and stratification variables were used to give unbiased national estimates of pre-
scription utilization and expenditures. All costs were inflated to 2011 dollars using 
the medical Consumer Price Index. Results: A total of 2782 survey respondents 
had at least one prescribed medicine associated with treatment of a neuropathic 
pain diagnosis, representing 2.9 million persons in 2005 and increasing to 3.9 million 
in 2011 (annual increase of 3.1%, p= 0.05). Both total prescriptions and total expendi-
tures peaked in 2008 ($1.1 billion(b) and 20.3 million (m) prescriptions, respectively), 
then declined through 2011. Narcotic analgesics and gabapentinoids were the drug 
classes with the largest mean annual expenditures ($305m and $211m) , followed by 
serotonin-noradrenalin reuptake inhibitors ($141m). Non-gabapentinoid anticon-
vulsants, tricyclic antidepressants, and topical analgesics had substantial declines 
in usage and expenditures from 2005 to 2011. Non-narcotic analgesics utilization 
and expenses, including NSAIDs and tramadol, remained largely stable during the 
study period. ConClusions: Prescription medications for peripheral neuropathic 
pain treatment experienced large swings in usage and expenditures from 2005-
2011, peaking in 2008 despite steady increases in the number of neuropathic pain 
medication users.
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objeCtives: This study examined patient age and gender as well as racial and 
geographic variations in the prevalence of cystic fibrosis (CF), a chronic lung 
disease common in children and young adults, in the U.S. Medicaid popula-
tion. Methods: A retrospective study was performed among the U.S. Medicaid 
fee-for-service (FFS) population from 2008 through 2009. CF patients were 
identified using International Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM) diagnosis code 277.0x. Patients with continuous Medicaid 
FFS enrollment in both 2008 and 2009 were included for analysis. Any managed 
care enrollment during the period was not permitted. CF prevalence was stratified 
by region, state, age, gender and race, for all patients and measured by number and 
percentage, in each category. Results: A total of 2,550 patients were diagnosed 
with CF among the Medicaid FFS population in 2008 and 2009. Prevalence was the 
highest (0.15%) for patients under age 40 years, followed by patients age 40 to 59 
(0.03%), and 60+ (0.01%). CF prevalence by race was also examined, with the follow-
ing results: White (0.06%), Hispanic (0.04%), Black (0.03%), Native American (0.02%) 
and Asian (0.02%). Male patients had a relatively higher prevalence compared to 
female patients (0.06% vs. 0.05%). Geographic variation was also analyzed, and 
the highest CF prevalence was observed in Minnesota (0.16%), followed by Ohio, 
Maryland, North Dakota (all at 0.11%) and West Virginia (0.09%). Patients residing 
in the Midwest had the highest prevalence rate (0.07%), compared to the Northeast 
(0.05%), South (0.04%) and West (0.03%). ConClusions: Statistical evidence shows 
that younger patients have a higher probability of being diagnosed with CF, with 
white patients more likely to be diagnosed with CF compared to those of other 
races. Male patients who resided in the Midwest U.S. region were also found to be 
at higher risk for a CF diagnosis.
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optimize spending on MS treatments and for clinical experts looking for improved 
understanding of the therapeutic benefits of natalizumab.
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objeCtives: This research was conducted to provide a systematic pairwise com-
parison of all available botulinum toxin type A treatments for cervical dystonia 
(CD) as there is a lack of direct head to head clinical trial data evidence. Three 
botulinum toxin type A products have been approved by the FDA for managing CD: 
AbobotulinumtoxinA, OnabotulinumtoxinA and IncobotulinumtoxinA. A pair-wise 
efficacy comparison was performed for all three toxins based on literature-reported 
clinical outcomes. Methods: Multi-armed randomized controlled trials (RCTs) for 
inclusion were identified using a systematic literature review. RCTs were assessed 
for comparability based on patient population and comparable efficacy outcome 
measures. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total 
score was selected as the efficacy outcome measurement for assessment. A mixed 
treatment comparison (MTC) was conducted using a Bayesian hierarchical model 
allowing indirect comparison of the efficacies of the interventions. Results: The 
network of six RCTs with fourteen arms formed a linear series of “steps” which 
facilitated the comparison of all botulinum toxin type A treatments of interest. 
Due to the limitation of available clinical data, this study only investigated the 
main effect of toxin treatments without explicitly considering potential confound-
ing factors such as gender and formulation differences. There was reasonable 
agreement between the number of unconstrained data points, residual deviance 
and pair-wise results, suggesting a coherent network. The results for TWSTRS 
total scale change from baseline for all treatments were: Placebo (mean -4.487, 
SE 1.402), AbobotulinumtoxinA (mean -11.08, SE 1.41), OnabotulinumtoxinA (mean 
-11.77, SE 1.44) and IncobotulinumtoxinA (mean -12.38, SE 1.79); where a negative 
number indicates symptom improvement. ConClusions: This research suggests 
that all botulinum toxin type A treatments were effective compared to placebo 
in cervical dystonia. However, based on this MTC analysis, there is no significant 
efficacy difference between AbobotulinumtoxinA, OnabotulinumtoxinA and 
IncobotulinumtoxinA.
PND5
outcomes iN schizoPhreNia: What Does “cliNically meaNiNgFul” 
meaN to Payers?
Kilburg A.1, Galani Berardo C.2, Souto D.1, Llorca P.M.3
1Wellmera AG, Basel, Switzerland, 2F. Hoffmann – La Roche Ltd., Basel, Switzerland, 3Centre 
Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
objeCtives: The understanding of the clinical meaningfulness of outcomes in 
schizophrenia is important to determine the value of new treatments for patients, 
caregivers, practitioners and payers. The aim of this research was to provide an 
overview of general concepts and methodologies applied to determine meaningful-
ness of endpoints, to describe how outcomes are measured in schizophrenia and 
how treatment success and clinical meaningfulness are defined in schizophrenia 
from a Health Technology Assessment (HTA) perspective. Methods: We conducted 
a targeted literature search focusing on antipsychotic treatment and clinical mean-
ingfulness of schizophrenia outcomes, a review of HTA submission guidelines, HTA 
reports in schizophrenia, a survey on individual country requirements in sixteen 
countries and an analogue analysis to identify payer definitions of clinical meaning-
ful differences. Results: No consistent approach exists from payers, or in the liter-
ature, to determine clinical meaningfulness in schizophrenia outcomes. Historically, 
payers have based their value assessments of antipsychotics on available clinical 
evidence using systematic literature reviews and meta-analyses. Most widely used 
efficacy endpoints in antipsychotic trials are changes in PANSS scores, BPRS and CGI 
(CGI-I and/or CGI-S). Payers noted considerable variation in the definition of clini-
cal meaningfulness to determine treatment response (20%-60% change in PANSS 
or BPRS score from baseline). Payers recommend validity should be demonstrated 
for clinical relevance of change on these endpoints using anchors such as patient-
reported, functional and global outcomes. Overall, payers suggest establishing a 
minimal clinically important difference (MCID) based on robust scientific criteria. 
Beyond the traditional clinical measures, payers would like to see complementary 
evidence on quality of life, patient satisfaction, family burden, resource utilization 
and hospitalization. ConClusions: Approaches to determine clinical meaningful-
ness in schizophrenia outcomes vary widely. Further research is needed to validate 
the meaningfulness of changes in commonly used clinical endpoints and generate 
additional payer relevant evidence on patient and caregiver burden.
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objeCtives: To examine the association between antidepressant drug use and C 
– Reactive Protein (CRP) among adults with inflammatory medical conditions after 
controlling for gender, race, age, income, Non-steroidal anti-inflammatory drug use, 
smoking, perceived health status, alcohol use and physical activity. Methods: 
Retrospective cross-sectional study with linked data from laboratory, prescription 
medication, medical conditions and demographic files of the National Health and 
Nutritional examination Survey (NHANES). The study sample (N = 3,492) consisted of 
adults (≥ 20 years) with any inflammatory condition (arthritis, gout, chronic obstruc-
